EVOK EVOKE PHARMA INC Capital Structure Changes 8-K Filing 2024 - Compliance with Nasdaq Listing Rule 5550(b)(1) Evoke Pharma regains compliance with Nasdaq's minimum stockholders equity requirement and will be subject to a discretionary panel monitor for one year.Get access to all SEC 8-K filings of the EVOKE PHARMA INC